Inhaled Corticosteroids for the Treatment of Transient Tachypnea of the Newborn
Inhaled Corticosteroids for the Treatment of Transient Tachypnea of the Newborn
Transient Tachypnea of the Newborn (TTN) is a common respiratory disorder affecting late
 preterm and term babies caused by lung edema resulting from delayed absorption of fetal
 alveolar lung fluid.

 The investigators hypothesize that ENAC expression will be up-regulated as a result of
 administration of corticosteroids. This effect will lead to enhanced absorption of fetal lung
 fluid finally treating TTN. The aim of our study will be to evaluate whether inhaled
 corticosteroids reduce respiratory distress and morbidity in late preterm and term neonates
 presenting with TTN.
The primary outcome measure will be the assessment of respiratory distress reflected by TTN
 clinical score in neonates presenting with TTN and treated with inhaled corticosteroids
 compared to placebo.
Inclusion Criteria:

 -  Late preterm and term infants (post-menstrual age ≥ 34 weeks) delivered by cesarean
 section or vaginal delivery

 -  Diagnosis of TTN

 -  Parents signed informed consent

 Exclusion Criteria:

 -  Meconium aspiration syndrome

 -  Respiratory distress syndrome

 -  Congenital heart disease

 -  Non respiratory disorders causing tachypnea